Incorporated in 2018, Amberstone Biosciences is an emerging biotherapeutics company developing a novel class of targeted and conditionally active immunotherapeutics to treat solid tumor cancers and other diseases. Amberstone Biosciences' pipeline is driven by an innovative high-throughput single-cell functional discovery platform and strong expertise in an interdisciplinary field of biology, engineering, and therapeutic development.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/03/22 | $12,000,000 | Series A |
ChangRong Capital Co-win Ventures  Lifespan Investments Sinovation Ventures Viva BioInnovator | undisclosed |
